Motavizumab
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is currently being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants.
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is currently being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants.
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |